Sequential immunotherapy regimens-expect the unexpected

Affiliations

¹ Christie NHS Foundation Trust, Manchester M20 4BX UK.
² Christie NHS Foundation Trust, Manchester M20 4BX UK; Institute of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.

Comment

Patricio Serra-Bellver et al. Lancet Oncol. 2016 Jul.

. 2016 Jul;17(7):854-855.

doi: 10.1016/S1470-2045(16)30198-X. Epub 2016 Jun 4.

¹ Christie NHS Foundation Trust, Manchester M20 4BX UK.
² Christie NHS Foundation Trust, Manchester M20 4BX UK; Institute of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.

No abstract available

Comment on

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS. Weber JS, et al. Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269740 Free PMC article. Clinical Trial.